hydroxychloroquine has been researched along with Clinically Isolated CNS Demyelinating Syndrome in 3 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "It has been shown that following demyelination, Oligodendrocyte Progenitor Cells (OPCs) migrate to the lesion site and begin to proliferate, and differentiate." | 5.62 | Analysis of platelet-derived growth factor receptor A and oligodendrocyte transcription factor 2 markers following Hydroxychloroquine administration in animal induced multiple sclerosis model. ( Aliomrani, M; Eftekhari, SM; Safaei, HA, 2021) |
| "It has been shown that following demyelination, Oligodendrocyte Progenitor Cells (OPCs) migrate to the lesion site and begin to proliferate, and differentiate." | 1.62 | Analysis of platelet-derived growth factor receptor A and oligodendrocyte transcription factor 2 markers following Hydroxychloroquine administration in animal induced multiple sclerosis model. ( Aliomrani, M; Eftekhari, SM; Safaei, HA, 2021) |
| "A case of transverse myelopathy in systemic lupus erythematosus with subacute onset and fatal course is reported." | 1.26 | [Transverse myelopathy and systemic lupus erythematosus. Report of a case and review of the literature]. ( Borges, TM; de Macedo, DD; de Mattos, JP, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Safaei, HA | 1 |
| Eftekhari, SM | 1 |
| Aliomrani, M | 1 |
| Lu, JQ | 1 |
| Ringrose, J | 1 |
| Gross, D | 1 |
| Emery, D | 1 |
| Blevins, G | 1 |
| Power, C | 1 |
| de Macedo, DD | 1 |
| de Mattos, JP | 1 |
| Borges, TM | 1 |
3 other studies available for hydroxychloroquine and Clinically Isolated CNS Demyelinating Syndrome
| Article | Year |
|---|---|
Analysis of platelet-derived growth factor receptor A and oligodendrocyte transcription factor 2 markers following Hydroxychloroquine administration in animal induced multiple sclerosis model.
Topics: Animals; Corpus Callosum; Cuprizone; Demyelinating Diseases; Disease Models, Animal; Hydroxychloroqu | 2021 |
Multifocal inflammatory demyelination in a patient with rheumatoid arthritis and treatment complications.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Brain; Demyelinating Diseases; Fatal Outcome; Female; H | 2016 |
[Transverse myelopathy and systemic lupus erythematosus. Report of a case and review of the literature].
Topics: Adolescent; Demyelinating Diseases; Dexamethasone; Drug Therapy, Combination; Female; Humans; Hydrox | 1979 |